Perkins Coie Trust Co Lowers Stock Position in Medtronic PLC $MDT

Perkins Coie Trust Co decreased its holdings in shares of Medtronic PLC (NYSE:MDT) by 98.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 639 shares of the medical technology company’s stock after selling 38,106 shares during the period. Perkins Coie Trust Co’s holdings in Medtronic were worth $50,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MDT. Fulton Bank N.A. boosted its stake in shares of Medtronic by 65.1% in the second quarter. Fulton Bank N.A. now owns 29,675 shares of the medical technology company’s stock valued at $2,321,000 after buying an additional 11,702 shares in the last quarter. Paladin Wealth LLC raised its position in Medtronic by 2.4% in the second quarter. Paladin Wealth LLC now owns 10,485 shares of the medical technology company’s stock worth $820,000 after acquiring an additional 245 shares in the last quarter. First Bank & Trust acquired a new stake in Medtronic in the second quarter valued at $1,953,000. Shrier Wealth Management LLC lifted its holdings in Medtronic by 5.8% in the second quarter. Shrier Wealth Management LLC now owns 7,014 shares of the medical technology company’s stock valued at $549,000 after acquiring an additional 385 shares during the period. Finally, Franklin Street Advisors Inc. NC boosted its position in shares of Medtronic by 12.5% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 37,099 shares of the medical technology company’s stock worth $2,902,000 after purchasing an additional 4,122 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a “turnaround” underway at the company. The upgrade suggests improving execution and renewed confidence in Medtronic’s ability to return to sustainable growth. Is Medtronic Becoming a Turnaround Story?
• Positive Sentiment: Medtronic is being promoted as an undervalued dividend-growth company, which may attract income-focused investors if the market begins to recognize potential for operational improvement and valuation expansion. Medtronic: Buy This Undervalued Dividend Aristocrat
• Positive Sentiment: Medtronic’s collaboration with Orchestra BioMed is progressing: the BACKBEAT pivotal trial remains on track to reach its enrollment target by the end of the third quarter of 2026, with primary data expected in the second quarter of 2027. Successful results could support future device-related growth. Orchestra BioMed Reports Second Quarter 2026 Results
• Neutral Sentiment: Recent coverage highlights Medtronic’s appeal relative to Johnson & Johnson and Abbott, but portrays the company more as a turnaround and valuation opportunity than a consistent high-growth story. Investors may continue to favor peers with stronger near-term organic growth. Johnson & Johnson vs. Medtronic Abbott vs. Medtronic

Medtronic Price Performance

Shares of NYSE:MDT opened at $89.31 on Tuesday. The business’s fifty day moving average price is $82.25 and its two-hundred day moving average price is $86.55. The stock has a market cap of $114.32 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 2.34 and a beta of 0.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the previous year, the firm posted $1.62 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts forecast that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were given a dividend of $0.72 per share. The ex-dividend date was Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a yield of 3.2%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Analyst Ratings Changes

MDT has been the topic of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $91.00 price target on shares of Medtronic in a research note on Monday, July 13th. Needham & Company LLC reissued a “buy” rating and set a $101.00 price objective on shares of Medtronic in a report on Wednesday, June 17th. Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Rothschild & Co Redburn dropped their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.83.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).